A prospective, multi centre, randomized clinical study to compare the efficacy and safety of Ertapenem 3 days versus Ampicillin-Sulbactam 3 days in the treatment of localized community acquired intra-abdominal infection. (T.E.A. Study: Three days Ertapenem vs three days Ampicillin-sulbactam)

Federico Coccolini, Fausto Catena, Luca Ansaloni, Giorgio Ercolani, Salomone Di Saverio, Filippo Gazzotti, Daniel Lazzareschi, Antonio D Pinna, Federico Coccolini, Fausto Catena, Luca Ansaloni, Giorgio Ercolani, Salomone Di Saverio, Filippo Gazzotti, Daniel Lazzareschi, Antonio D Pinna

Abstract

Background: The recommendations outlined in the latest guidelines published by the Surgical Infection Society (SIS) and the Infectious Disease Society of America (IDSA) regarding the proper duration of antibiotic therapy in patients with intra-abdominal infections are limited and non-specific. This ambiguity is due mainly to the lack of clinical trials on the topic of optimal duration of therapy. It is well known that the overuse of antibiotics has several important consequences such as increased treatment costs, reduced clinical efficacy, and above all, the increased emergence of antibiotic-resistant pathogens. Ampicillin-Sulbactam is a commonly used "first line" antibiotic for intra-abdominal infections. Ertapenem and Ampicillin-sulbactam are recommended as primary treatment agents for localized peritonitis by both the SIS and IDSA guidelines.

Methods/design: This study is a prospective multi-center randomized investigation. The study will be performed in the Departments of General, Emergency, and Transplant Surgery of Sant'Orsola-Malpighi University Hospital in Bologna, Italy, in the General Surgery Department of the Ospedali Riuniti of Bergamo, Italy, and in the Trauma and Emergency Surgery Department of Maggiore Hospital in Bologna, Italy, and will be conducted by all surgeons willing to participate in the study. The inclusion period of the study will take approximately two years before the planned number of 142 enrolled patients is reached.

Discussion: Ertapenem and Ampicillin-sulbactam are recommended both as primary treatment agents for localized peritonitis by both the SIS and IDSA guidelines. As one of the discussed topic is the optimal duration of the antibiotic therapy and this ambiguity is due mainly to the lack of clinical trials on the topic, the present study aims for obtain precise data.

Trial registration: ClinicalTrials.gov: NCT00630513.

References

    1. Mazuski JE, Sawyer RG, Nathens AB, DiPiro JT, Schein M, Kudsk KA, Yowler C. Therapeutic Agents Committee of the Surgical Infections Society. The Surgical Infection Society guidelines on antimicrobial therapy for intra-abdominal infections: evidence for the recommendations. Surg Infect (Larchmt) 2002;3(3):175–233. doi: 10.1089/109629602761624180. Fall.
    1. Meakins JL, Solomkin JS, Allo MD, Dellinger EP, Howard RJ, Simmons RL. A proposed classification of intra-abdominal infections. Arch Surg. 1984;119:1372–1378.
    1. Barie PS. Modern surgical antibiotic prophylaxis and therapy--less is more. Surg Infect (Larchmt) 2000;1(1):23–9. doi: 10.1089/109629600321263. Review.
    1. Nichols RL. Intraabdominal infections: An overview. Rev Infect Dis. 1985;7(S4):S709–S715. doi: 10.1093/clinids/7.Supplement_4.S709.
    1. Snelling CM, Poenaru D, Drover JW. Minimum postoperative antibiotic duration in advanced appendicitis in children: a review. Pediatr Surg Int. 2004;20(11-12):838–45. doi: 10.1007/s00383-004-1280-x.
    1. Basoli G. A prospective, randomized, double-blind, multicenter, controlled clinical study to compare the efficacy and safety of Ertapenem 3 days vs Ertapenem standard duration in the treatment of localized community-acquired IAI. J of Gastrointest Surgery. in press .
    1. el Moussaoui et al.Effectiveness of discontinuing antibiotic treatment after three days versus eight days in mild to moderate-severe community acquired pneumonia: randomised, double blind study. BMJ. 2006;332(7554):1355. doi: 10.1136/bmj.332.7554.1355.
    1. Geroulanos SJ. the Meropenem Study Group. Meropenem versus imipenem/cilastatin in intra-abdominal infections rquiring surgery. J Antimicrob Chemother Suppl.A. 1995;36:191–205.
    1. Wilson SE. Carbapenem: monotherapy in intra-abdominal sepsis. Scand J Infect Dis Suppl. 1995;96:28–33.
    1. Levison ME, Bush LM. In: Peritonitis and other intra-abdominal infections. Mandell GL, et al, editor. New York: Churchill Livingstone; 1990. pp. 636–670. Principles and practice of infectious diseases.
    1. Bohnen JMA, Mustard RA, Oxholm SE, Schouten BD. APACHE II score and abdominal sepsis - A prospective study. Arch Surg. 1988;123:225–229.
    1. Dela Pena AS, Asperger W, Kockerling F, Raz R, Kafka R, Warren B, Shivaprakash M, Vrijens F, Giezek H, DiNubile MJ, Chan CY. Efficacy and safety of ertapenem versus piperacillin-tazobactam for the treatment of intra-abdominal infections requiring surgical intervention. J Gastrointest Surg. 2006;10(4):567–74. doi: 10.1016/j.gassur.2005.06.015.
    1. Abstract Book of the Word Society of Emergency Surgery (WSES) Congress, Bologna, Italy, July 2010, pag. 61

Source: PubMed

Sponsorzy i współpracownicy

Warunki medyczne

Interwencje lekowe

3
Subskrybuj